Amarin inks licensing deal with CSL for heart drug Vazkepa in Australia, New Zealand
fotostorm
- Amarin (NASDAQ:AMRN) is licensing exclusive rights to Vazkepa to CSL Seqirus to secure pricing and reimbursement, and sell the heart drug in Australia and New Zealand.
- Under the agreement, Amarin will receive an upfront payment and be eligible for event-related milestone payments of up to about $8M and additional product-related milestone payments of up to ~$4M.
- Amarin will be responsible for supplying finished product to CSL Seqirus at a profitable transfer price paid to Amarin, according to the companies.
- CSL Seqirus, a unit of CSL (OTCPK:CSLLY), will be responsible for market access and reimbursement, distribution, and commercial promotion of Vazkepa (icosapent ethyl) capsules in Australia and New Zealand.
- Vazkepa, is also sold as Vascepa, to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides and established cardiovascular disease or diabetes and at least one other cardiovascular risk factor.